Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
May 19, 2026 updated by: Merck Sharp & Dohme LLC
An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03)
Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn:
- About the safety of the study treatments and if people tolerate them
- If people who receive patritumab deruxtecan, pembrolizumab, and chemotherapy before surgery have fewer cancer cells removed during surgery compared to those who receive only pembrolizumab (pembro) and chemotherapy.
Study Overview
Status
Recruiting
Conditions
Study Type
Interventional
Enrollment (Estimated)
372
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Toll Free Number
- Phone Number: 1-888-577-8839
- Email: Trialsites@msd.com
Study Locations
-
-
-
Seoul, South Korea, 03080
- Recruiting
- Seoul National University Hospital ( Site 2400)
-
Contact:
- Study Coordinator
- Phone Number: +82220720850
-
Seoul, South Korea, 05505
- Recruiting
- Asan Medical Center ( Site 2401)
-
Contact:
- Study Coordinator
- Phone Number: +82230103217
-
Seoul, South Korea, 03722
- Recruiting
- Severance Hospital, Yonsei University Health System ( Site 2402)
-
Contact:
- Study Coordinator
- Phone Number: +82222288135
-
-
-
-
-
Córdoba, Spain, 14004
- Recruiting
- Hospital Universitario Reina Sofia ( Site 1702)
-
Contact:
- Study Coordinator
- Phone Number: +34 957012408
-
-
Catalonia
-
Badalona, Catalonia, Spain, 08916
- Recruiting
- Institut Català d'Oncologia (ICO) - Badalona ( Site 1700)
-
Contact:
- Study Coordinator
- Phone Number: +34934978925
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Spain, 28027
- Recruiting
- Clinica Universidad de Navarra ( Site 1703)
-
Contact:
- Study Coordinator
- Phone Number: +34913531920
-
-
-
-
-
Taichung, Taiwan, 407
- Recruiting
- Taichung Veterans General Hospital ( Site 2502)
-
Contact:
- Study Coordinator
- Phone Number: +886423592525
-
Tainan, Taiwan, 704
- Recruiting
- National Cheng Kung University Hospital ( Site 2503)
-
Contact:
- Study Coordinator
- Phone Number: +88662353535
-
Taipei, Taiwan, 112
- Recruiting
- Koo Foundation Sun Yat-Sen Cancer Center ( Site 2501)
-
Contact:
- Study Coordinator
- Phone Number: 886228970011x1686
-
-
-
-
California
-
Santa Monica, California, United States, 90404
- Recruiting
- UCLA Hematology/Oncology - Parkside ( Site 0021)
-
Contact:
- Study Coordinator
- Phone Number: 424-402-9520
-
-
Illinois
-
Skokie, Illinois, United States, 60077
- Recruiting
- Orchard Healthcare Research Inc. ( Site 0006)
-
Contact:
- Study Coordinator
- Phone Number: 847-568-9932
-
-
Montana
-
Billings, Montana, United States, 59102
- Recruiting
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003)
-
Contact:
- Study Coordinator
- Phone Number: 406-238-6685
-
-
Oregon
-
Tigard, Oregon, United States, 97223
- Recruiting
- Northwest Cancer Specialists (Compass Oncology) ( Site 8003)
-
Contact:
- Study Coordinator
- Phone Number: 360-944-9889
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Recruiting
- SCRI Oncology Partners ( Site 7000)
-
Contact:
- Study Coordinator
- Phone Number: 844-482-4812
-
-
Texas
-
Dallas, Texas, United States, 75246
- Recruiting
- Texas Oncology - DFW ( Site 8000)
-
Contact:
- Study Coordinator
- Phone Number: 214-370-1067
-
Houston, Texas, United States, 77030
- Recruiting
- Houston Methodist Hospital ( Site 0022)
-
Contact:
- Study Coordinator
- Phone Number: 713-441-9948
-
-
Virginia
-
Norfolk, Virginia, United States, 23502
- Recruiting
- Virginia Oncology Associates (VOA) ( Site 8001)
-
Contact:
- Study Coordinator
- Phone Number: 844-482-4812
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has locally advanced, non-metastatic (M0), breast cancer, defined as any of the following combined primary tumor (T) and regional lymph node (N) staging per current American Joint Committee on Cancer (AJCC) criteria: cT1c, N1-N2; cT2, N0-N2; cT3, N0-N2; or cT4a-d, N0-N2
- Has centrally confirmed diagnosis of breast cancer that is triple-negative or HR-low+/HER2- breast cancer that will be treated according to the triple-negative breast cancer (TNBC) paradigm
- Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
- Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 28 days prior to allocation/randomization
- Has left ventricular ejection fraction (LVEF) of ≥50% or ≥ lower limit of normal (LLN) as assessed by echocardiogram (ECHO) or multigate acquisition scan (MUGA) scan
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has uncontrolled or significant cardiovascular disease before randomization
- Has any history of or evidence of any current leptomeningeal carcinomatosis.
- Has clinically significant corneal disease
- Has human immunodeficiency virus (HIV) infection with a history of Kaposi sarcoma and/or multicentric Castleman disease
- Has evidence of ongoing, uncontrolled, systemic bacterial, fungal, or viral infection
- Has received prior therapy with an anti-programmed death (PD)-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor
- Has received any prior treatment, including radiation, systemic therapy, and/or definitive surgery for currently diagnosed breast cancer
- Has received prior treatment with an anti-human epidermal growth factor receptor 3 (HER3) antibody and/or antibody-drug conjugate (ADC) that consists of an exatecan derivative that is a topoisomerase I inhibitor (e.g., trastuzumab deruxtecan)
- Has metastatic (Stage IV) breast cancer or cN3 nodal involvement
- Has known additional malignancy that is progressing or has required active treatment within the past 5 years
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, or current or suspected ILD
- Has an active infection requiring systemic therapy
- Has concurrent active HBV and HCV infection
- Has clinically severe respiratory compromise resulting from intercurrent pulmonary illness
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Part 1, A: Pembrolizimab + patritumab deruxtecan → Pembrolizumab + paclitaxel + carboplatin
In Part 1, participants receive neoadjuvant pembrolizumab 200 mg via intravenous (IV) infusion every 3 weeks (Q3W) plus patritumab deruxtecan via IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg via IV infusion Q3W plus paclitaxel 80 mg/m^2 via IV infusion every week (QW) and carboplatin AUC1.5 mg/ml/min via IV infusion QW for 12 weeks.
At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer.
|
Administered via IV infusion as neoadjuvant treatment
Other Names:
Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
Other Names:
Administered via IV infusion as neoadjuvant treatment
Other Names:
Administered via IV infusion as neoadjuvant treatment
Other Names:
|
|
Experimental: Part 2, A: Pembrolizimab + patritumab deruxtecan → Pembrolizumab + paclitaxel + carboplatin
In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion every Q3W plus patritumab deruxtecan (dose to be determined in part 1) IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min IV infusion QW for 12 weeks.
At 3-6 weeks after last dose of neoadjuvant treatment, participants undergo surgery for breast cancer.
After surgery, participants receive adjuvant pembrolizumab 400 mg IV every 6 weeks (Q6W) for ~30 weeks.
Additional adjuvant treatment of physician's choice (TPC) may be given to participants with residual disease.
TPC options are olaparib 300 mg oral twice daily (BID) for 1 year (participants with germline BRCA mutation [gBRCAm] only), capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles or doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV Q3W or every 2 weeks (Q2W) and cyclophosphamide 600 mg/m^2 IV Q3W or Q2W for 4 doses.
|
Administered via IV infusion as neoadjuvant treatment
Other Names:
Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
Other Names:
Administered via IV infusion as neoadjuvant treatment
Other Names:
Administered via IV infusion as neoadjuvant treatment
Other Names:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Other Names:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Other Names:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Other Names:
Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2
Other Names:
Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2
Other Names:
|
|
Experimental: Part 2, B: Pembrolizumab + paclitaxel + carboplatin → Pembrolizumab + patritumab deruxtecan
In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min IV infusion QW for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus patritumab deruxtecan (dose to be determined in part 1) via IV infusion Q3W for 12 weeks.
At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer.
After surgery, participants will receive adjuvant pembrolizumab 400 mg IV infusion Q6W for ~30 weeks.
Additional adjuvant TPC may be administered to participants with residual disease.
TPC options include olaparib 300 mg oral BID for 1 year (participants with gBRCAm only), capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles or doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV infusion Q3W or Q2W and cyclophosphamide 600 mg/m^2 IV infusion Q3W or Q2W for 4 doses.
|
Administered via IV infusion as neoadjuvant treatment
Other Names:
Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
Other Names:
Administered via IV infusion as neoadjuvant treatment
Other Names:
Administered via IV infusion as neoadjuvant treatment
Other Names:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Other Names:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Other Names:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Other Names:
Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2
Other Names:
Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2
Other Names:
|
|
Active Comparator: Part 2, C: Pembro + paclitaxel + carboplatin→ Pembro + doxorubicin (or epirubicin) +cyclophosphamide
In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min via IV infusion QW for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV infusion Q3W and cyclophosphamide 600 mg/m^2 IV infusion Q3W for 12 weeks.
At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer.
After surgery, participants will receive adjuvant pembrolizumab 400 mg IV infusion Q6W for approximately 30 weeks.
Additional adjuvant TPC may be administered to participants with residual disease.
TPC options include olaparib 300 mg oral BID for 1 year (participants with gBRCAm only) or capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles.
|
Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
Other Names:
Administered via IV infusion as neoadjuvant treatment
Other Names:
Administered via IV infusion as neoadjuvant treatment
Other Names:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Other Names:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Other Names:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Other Names:
Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2
Other Names:
Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Part 1: Number of Participants Experiencing an Adverse Event (AE)
Time Frame: Up to ~43 weeks
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment.
The number of participants who experience an AE will be presented for Part 1.
|
Up to ~43 weeks
|
|
Part 1: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)
Time Frame: Up to 21 days
|
A DLT is defined by the National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) Version 5.0, assessed by investigator as drug-related: Grade (gr) 3 or 4 nonhematologic toxicity (with exceptions); gr 3 or gr 4 laboratory values (with exceptions); gr 3 or 4 febrile neutropenia; prolonged delay (>2 weeks) in initiating Cycle 2 (cycle length = 3 weeks) due to intervention-related toxicity; any intervention-related toxicity that causes the participant to discontinue intervention during Cycle 1; interstitial lung disease as per investigator; any other gr ≥3 pulmonary toxicity; or gr 5 toxicity.
|
Up to 21 days
|
|
Part 1: Number of Participants who Discontinued Study Treatment Due to an AE
Time Frame: Up to ~30 weeks
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment.
The number of participants who discontinued study treatment due to an AE will be presented for Part 1.
|
Up to ~30 weeks
|
|
Part 2: Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0
Time Frame: Up to ~30 weeks
|
pCR (ypT0/Tis ypN0) is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy at the time of definitive surgery.
|
Up to ~30 weeks
|
|
Part 2: Number of Participants Experiencing an AE
Time Frame: Up to ~103 weeks
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment.
The number of participants who experience an AE will be presented for Part 2.
|
Up to ~103 weeks
|
|
Part 2: Number of Participants who Discontinued Study Treatment Due to an AE
Time Frame: Up to ~90 weeks
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment.
The number of participants who discontinued study treatment due to an AE will be presented for Part 2.
|
Up to ~90 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Part 2: pCR-No Ductal Carcinoma in Situ (DCIS) Rate Using the Definition of ypT0 ypN0
Time Frame: Up to ~30 weeks
|
pCR-no DCIS (ypT0 ypN0) is defined as the absence of residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy at the time of definitive surgery.
|
Up to ~30 weeks
|
|
Part 2: Event-Free Survival (EFS)
Time Frame: Up to ~100 months
|
EFS is defined as the time from randomization to disease progression that precludes surgery, local or distant recurrence, or death due to any cause, whichever occurs first.
|
Up to ~100 months
|
|
Part 2: Overall Survival (OS)
Time Frame: Up to ~100 months
|
OS is defined as the time from randomization to date of death due to any cause.
|
Up to ~100 months
|
|
Part 2: Distant Progression or Distant Recurrence-Free Survival (DPDRFS)
Time Frame: Up to ~100 months
|
DPDRFS is defined as the time from randomization to first distant progression or distant recurrence event as assessed or death due to any cause, whichever occurs first.
|
Up to ~100 months
|
|
Part 2: Residual Cancer Burden (RCB)
Time Frame: Up to ~30 weeks
|
RCB is defined as residual disease in either the breast or lymph node at the time of surgery.
RCB score provides a continuous measurement of the extent of residual cancer.
There are four RCB classes: RCB-0 (RCB score 0), RCB-1 (0< RCB score <1.36), RCB-2 (1.36 <RCB score <3.28), and RCB-3 (RCB score >3.28).
|
Up to ~30 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Medical Director, Merck Sharp & Dohme LLC
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 20, 2025
Primary Completion (Estimated)
December 31, 2029
Study Completion (Estimated)
December 31, 2034
Study Registration Dates
First Submitted
January 21, 2025
First Submitted That Met QC Criteria
January 21, 2025
First Posted (Actual)
January 28, 2025
Study Record Updates
Last Update Posted (Actual)
May 20, 2026
Last Update Submitted That Met QC Criteria
May 19, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Skin Diseases
- Breast Diseases
- Skin and Connective Tissue Diseases
- Breast Neoplasms
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Nucleic Acids, Nucleotides, and Nucleosides
- Hydrocarbons
- Cycloparaffins
- Hydrocarbons, Alicyclic
- Hydrocarbons, Cyclic
- Terpenes
- Carbohydrates
- Polycyclic Aromatic Hydrocarbons
- Hydrocarbons, Aromatic
- Polycyclic Compounds
- Glycosides
- Coordination Complexes
- Taxoids
- Cyclodecanes
- Diterpenes
- Deoxycytidine
- Cytidine
- Pyrimidine Nucleosides
- Pyrimidines
- Phosphoramide Mustards
- Nitrogen Mustard Compounds
- Mustard Compounds
- Hydrocarbons, Halogenated
- Phosphoramides
- Organophosphorus Compounds
- Nucleosides
- Uracil
- Pyrimidinones
- Anthracyclines
- Naphthacenes
- Aminoglycosides
- Daunorubicin
- Deoxyribonucleosides
- Fluorouracil
- Capecitabine
- Cyclophosphamide
- Carboplatin
- Doxorubicin
- Paclitaxel
- Epirubicin
- pembrolizumab
- olaparib
- patritumab deruxtecan
Other Study ID Numbers
- 1022-010
- MK-1022-010 (Other Identifier: MSD)
- U1111-1307-7867 (Registry Identifier: UTN)
- 2024-514376-40-00 (Registry Identifier: EU CT)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on Patritumab deruxtecan
-
SCRI Development Innovations, LLCDaiichi SankyoCompletedMetastatic Breast Cancer | Locally Advanced Breast CancerUnited States
-
The Netherlands Cancer InstituteDaiichi SankyoRecruitingEGFR Gene Mutation | Non-Small Cell Lung Carcinoma | Advanced Non-Small Cell Squamous Lung CancerNetherlands
-
MedSIRDaiichi SankyoCompletedMetastatic Breast Cancer | Solid Tumor, Adult | Advanced Non-Small Cell Squamous Lung CancerSpain, Austria
-
Samsung Medical CenterRecruitingSolid Tumor, AdultSouth Korea
-
Daiichi SankyoMerck Sharp & Dohme LLCRecruitingMelanoma | Cervical Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Esophageal Cancer | Lung Cancer | Prostate Cancer | Bladder Cancer | Advanced Solid Tumor | Endometrial Cancer | Non-small Cell Lung Cancer (NSCLC) | Ovarian Carcinoma | Pancreatic CarcinomaCanada, United States, Belgium, Spain, Netherlands, Japan, Taiwan, France, Norway, Italy, China, United Kingdom, Australia, Germany, Hungary, South Korea
-
Daiichi SankyoTerminatedMetastatic Colorectal CancerUnited States, Spain, Belgium, Japan, France, United Kingdom, Italy, Poland
-
Merck Sharp & Dohme LLCDaiichi SankyoRecruitingMalignant NeoplasmUnited States, Israel, France, Spain, Taiwan, South Korea, United Kingdom, Belgium, Netherlands, Denmark, Slovakia, Hungary, Italy, Brazil, Colombia, Germany, Czechia, Turkey (Türkiye), Australia, Sweden, Greece, Canada, Chile
-
Daiichi SankyoMerck Sharp & Dohme LLC; Daiichi Sankyo Co., Ltd.Active, not recruitingNon-Small Cell Lung Cancer Metastatic | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorUnited States, Spain, France, United Kingdom, Taiwan, Australia, Japan, China, Netherlands, Italy, Belgium, Bulgaria, Germany, Singapore, South Korea, Austria
-
Daiichi Sankyo Co., Ltd.Merck Sharp & Dohme LLC; Daiichi SankyoCompletedMetastatic Breast CancerUnited States, Japan
-
Merck Sharp & Dohme LLCDaiichi SankyoRecruitingGastrointestinal CancerIsrael, Taiwan, United States, Australia, France, Spain, China, Italy, New Zealand, Canada, Switzerland, Chile, South Korea, Thailand, Turkey (Türkiye)